Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
October 13, 2009

Nine European Countries Sanction Six-Month Formulation of Debiopharm’s Prostate Cancer Medication

  • Debiopharm and its European marketing partner, Ipsen, confirmed regulatory approval of its prostate cancer drug in nine European countries: Germany (the reference member state), France, Austria, Finland, Norway, Belgium, Denmark, Spain, and The Netherlands. The sanction pertains to the six-month sustained-release formulation of Decapeptyl® and was given through the European decentralized procedure.

    The companies say that the this new formulation will probably be launched first in Germany, The Netherlands, and Spain. The new sustained-release LHRH agonist is indicated for the treatment of locally advanced or metastatic, hormone-dependent prostate cancer.

    Decapeptyl® is already available in monthly or quarterly sustained-release formulations as well as a daily formulation. The drugs are marketed worldwide for the treatment of advanced prostate cancer, endometriosis, precocious puberty, IVF applications, and uterine fibroids.


Related content

  • You’re all set! Thank you for subscribing to GEN Highlights.